Introduction
The diagnosis of invasive fungal diseases (IFD) based on clinical, radiological and microbiological findings is not reliable and is often delayed, which may result in increased morbidity and mortality. As cultures lack sensitivity and/or specificity, non-culture-based methods are increasingly used in the management of patients at risk of IFD. Among the available biomarkers, fungal Ags and molecular tests have been investigated as an aid to early diagnosis. In patients with hematological malignancies, biomarkers are mainly used as screening tests to prompt antifungal treatment. The revised version of the EORTC/MSG (European Organization for Research and Treatment of Cancer/Mycoses Study Group) consensus definitions 1 includes some biological markers (galactomannan (GM), b-glucan (BG), Cryptococcus Ag). Reliable and reproducible diagnostic performance, standardized inter-laboratory procedures, easy application, rapid availability of results and cost-effectiveness are the main features required for the use of a diagnostic test in routine clinical practice.
So far, consensus guidelines have focused on evidencebased treatment choices, without specific recommendations for the use of diagnostic tests or procedures. The third European Conference on Infections in Leukemia (ECIL-3) was held in September 2009, with the aim of attaining a consensus and providing recommendations for improved diagnosis of IFD. Four working groups were dedicated to the evidence-based assessment of the following noninvasive diagnostic procedures: GM for invasive aspergillosis (IA); BG for invasive candidiasis (IC) and IA; Cryptococcus Ag for cryptococcosis; mannan Ag (Mn)/ anti-mannan (A-Mn) Ab for IC, and PCR for IA.
A systematic literature review was based on a search strategy including PubMed Central, Embase and abstracts from the principal international infectious diseases and hemato-oncology meetings up to October 2010.
The main goal of ECIL is to elaborate recommendations for the management of infections in hematological patients. Most of the literature analyzed dealt with patients at a risk of IFD 45-10%, that is, acute leukemia patients with prolonged neutropenia and allogeneic hematopoietic SCT (HSCT) recipients. Therefore, extrapolation to other hematological disorders or other types of immunocompromised hosts should be cautious. The present manuscript is intended to support teams involved in the management of patients with hematological malignancies for the use of non-culture-based biomarkers in the diagnostic work-up strategy of IFD. Recommendations were graded on the basis of the quality of evidence ( Table 1 ). The slide sets of ECIL-3 have been made available since May 2010 on the websites of the four involved organizations. 2 
Galactomannan (GM)
GM is a fungal cell wall component of Aspergillus. Circulating GM can be detected in serum or plasma and the Ag may be present in bronchoalveolar lavage (BAL)-fluid, cerebrospinal fluid (CSF) or other body fluids. 3 A single commercial Enzyme immunoassay (EIA) is available for GM testing (Bio-rad Laboratories, Marne-La-Coquette, France). The EIA is a sandwich immunoassay, where the same MoAb is used to coat the wells and is also added to bind any GM in the biological sample. The cutoff is calculated by dividing the OD of the patient's sample by that of the threshold control, which contains 1 ng/L of GM. The concentration of GM is expressed as an index, and for serum (and plasma) a cutoff GM index for positivity of 0.5 is recommended. 3 The performance of GM testing has been thoroughly reviewed and reassessed in several recent meta-analyses. 4, 5 Important variations of the test performance have been observed among different patient groups and institutions. 5 Overall, a better performance is generally observed in patients undergoing intensive chemotherapy, such as patients with hematological malignancy (sensitivity: 58%, 95% confidence interval (CI): 52-64; specificity: 95%, 95% CI: 94-96) and following HSCT (sensitivity: 65%, 95% CI: 60-78; specificity: 65%, 95% CI: 44-83) when compared with that reported in solid-organ transplant recipients (sensitivity: 41%, 95% CI: 21-64; specificity: 85%, 95% CI: 80-89). 5 Differences in performance of the EIA are probably due to differences in the pathogenesis of Aspergillus diseases in various host groups. [6] [7] [8] [9] In neutropenic patients, angioinvasive aspergillosis occurs, which is associated with an invasion of blood vessels due to a poor immune response. In non-neutropenic patients, such as hematological patients after BM recovery or non-hematological patients treated with long-term corticosteroids and other immunosuppressive regimens, a significant local inflammation limiting the angio-invasive process occurs.
Testing for GM in serum is one of the three Ag detection systems included in the revised EORTC/MSG consensus definitions for IFD in cancer patients. 1, 10 GM has become an important diagnostic tool in the management of patients at risk for IA. Monitoring for GM may be used in neutropenic patients who have a relatively high a-priori probability (45-10%) of developing IA. These include patients with AML and myelodysplastic syndrome undergoing intensive chemotherapy, and patients receiving allogeneic HSCT in the early engraftment phase. These patients are admitted to the hospital during their period at high risk, and GM monitoring is recommended every 3-4 days. 11, 12 A diagnosis-driven strategy that incorporates prospective GM monitoring should be combined with highresolution computed tomography imaging, and appropriate clinical and microbiological evaluation. 11, 12 A single positive GM index of X0.7 or two consecutive samples of X0.5 should prompt a diagnostic work-up. 13 GM monitoring can be continued after antifungal therapy has been initiated. Several studies have shown that the course of the GM index during antifungal therapy is predictive of the outcome.
14 Persistent GM antigenemia during therapy is a poor prognostic sign and should prompt clinical reassessment.
In addition to blood, GM can be detected in CSF or BAL fluid. 9, 15 Pending a recommended cutoff by the manufacturer, a cutoff of 1 is used for these specimens. Although GM can also be detected in pleural fluid, sputum or urine, the experience with GM detection in these specimens is insufficient to formulate specific recommendations.
The specificity of GM EIA may be limited by the false positivity caused by numerous factors. [3] [4] [5] These include cross-reactivity with some beta-lactam antibiotics and with GM from other non-pathogenic fungal species, as well as the epidemiological and biological factors listed in Table 2 . Decreased sensitivity has been reported during exposure to mould-active antifungal agents, for instance in patients receiving posaconazole or voriconazole prophylaxis which may prevent the circulation of GM. 16 There is good evidence to support the use of GM for the diagnosis of IA in adult hemato-oncological patients (A II). A diagnosis-driven strategy that incorporates GM monitoring (combined with appropriate clinical and microbiological evaluation, and high-resolution computed tomography imaging) every 3-4 days is proposed (A II). Additional randomized controlled studies including a screening strategy based on GM combined with clinical, radiological and microbiological diagnostic assessment may further strengthen the evidence of its utility in the early management of IA, and provide data on its costeffectiveness. Recommendations for pediatric use need further assessment.
b-Glucan (BG)
BG antigenemia has also been included in the revised EORTC/MSG definitions for IFD. 1 1-3-b-D-glucan is a cell wall component in Candida spp., Aspergillus spp. and the majoritiy of other fungal species, with the exception of zygomycetes and Cryptococcus species. A total of four BG assays are commercially available for diagnostic use: Fungitell (Associates of Cape Cod, Inc., East Falmouth, MA, USA), Fungitec-G (Seikagaku, Kogyo, Tokyo, Japan), Wako (Wako Pure Chemical Industries, Ltd., Tokyo, Japan) and Maruha (Maruha-Nichiro, Foods Inc., Tokyo, Japan). The kits differ in the source of the substrate used for the chromogenic reaction, that is, the amoebocyte lysate from the horseshoe crab, Limulus polyphemus (North-America) or Tachypleus tridentatus (Japan). This results in different reactivities for BG detection and cutoffs for defining positivity of tests: Fungitell 60-80 pg/mL, Fungitec-G 20 pg/mL, Wako and Marhua 11 pg/mL. The Fungitell assay has been approved by the FDA and is available in the United States and Europe; the other three tests are available only in Japan.
By conducting a systematic review of the literature, we identified 13 case-control studies and 10 cohort studies (most of them using a twice to thrice weekly monitoring strategy) providing data on sensitivity and specificity of the above commercially available BG assays for the diagnosis of IFD. As the design of these studies was very variable, only 10 (4 case-control and 6 cohort studies) [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] were considered appropriate for analysis on the basis of the following parameters: type of population (hematological patients), sample size (X20 IFD cases and X50 non-IFD controls) and reference standard of IFD (definition according to the EORTC/MSG criteria). 10 Whereas sensitivity, specificity, positive and negative predictive values derived from these analyses in hematological patients were variable (Table 3) , no major differences were observed among the different assays. This variability may be partly explained by differences in the patient populations (variable proportions of acute leukemic vs allogeneic HSCT recipients, case-control vs cohort design, healthy volunteers vs patients at low risk vs patients at high risk of IFD as controls) and in the methodology (prospective vs retrospective design, inclusion of proven and probable IFD plus/minus possible cases according to EORTC/MSG criteria, single vs multiple sequential blood sampling). Overall, the results of cohort studies tend to exhibit a larger variability of test performance when compared with case-control studies. Different cutoffs for positivity have been investigated in seven studies, 17, [19] [20] [21] [22] 24, 26 suggesting that the optimal cutoff if compared with the recommended value may be lower for the Wako and Maruha assays 19, 26 and higher for the Fungitec-G assay. 21 The prerequisite of two consecutive positive tests for IFD diagnosis was investigated in four studies and resulted in a specificity approaching 100% and a lower sensitivity ranging between 45 and 65%. 17, 19, 23, 26 The diagnostic performance of BG was similar in IC and IA, while utility in other less common IFD could not be assessed because of lacking data. Few data on the timing of BG positivity compared with conventional diagnostic tools are available: one study suggested that BG detection might precede IFD diagnosis according to the EORTC/MSG criteria. 26 
Table 2
Biological and epidemiological factors that influence the performance of GM detection in invasive aspergillosis 3 
Biological factors Epidemiological factors
Site There is moderate evidence from well-conducted cohort or case-control studies (B II) to support a recommendation for the use of the BG test for diagnosis of IFD in high-risk hematological patients (acute leukemic patients with prolonged neutropenia after induction/consolidation chemotherapy or allogeneic HSCT recipients). Owing to variable sensitivity, specificity and predictive values, the BG test should be used for clinical management decisions in conjunction with clinical, microbiological and radiological findings. 27 Additional analyses are needed to determine the optimal cutoff values and the number of positive samples defining a positive test. Performance analyses should be investigated in cohort studies that better reflect the utility of the test in populations targeted in its real-life clinical application.
Many issues remain open and need to be addressed in further studies: (i) BG monitoring in high-risk patients (sequential measurements twice or thrice weekly during the period at risk of IFD vs measurements uniquely driven by clinical suspicion of IFD), (ii) diagnostic yield in allogeneic HSCT recipients, pediatric patients, IFD at different sites, biological fluids other than blood (for example, BAL, CSF), (iii) sequential use of this 'panfungal' test with other fungus-specific markers, (iv) timing of diagnosis and (v) utility in follow-up of IFD. Attention should be paid to the potential causes of false-negative results (ongoing antifungal prophylaxis or therapy, pathogenic fungi not detected by the BG assay, such as zygomycetes and Cryptococcus, non/semi-invasive fungal disease) and falsepositive results (blood transfusions or blood-derived products, hemodialysis/hemofiltration, beta-lactam antibiotics, Igs, cellulose dressings, contamination of specimens at bed-side or during pre-or analytical processing by organic dusts or wastes, bacterial infections). Issues regarding the technical complexity of the assay and the cost-effectiveness of its use should also be considered for its real-time implementation for guiding clinical management. 27 
Cryptococcus Ag
The main feature of the yeast, Cryptococcus neoformans, is that it is surrounded by a polysaccharide capsule. Testing methods for detecting Cryptococcus Ag in serum and CSF are latex agglutination or EIA, and a high concordance between the available tests has been found (490%). 28 Cryptococcus Ag detection has been included in the EORTC/MSG definitions of IFD. 1, 10 A systematic review of the manuscripts published after 1 January 1998 was performed in order to confirm the established utility of Cryptococcus Ag testing in disseminated cryptococcosis, Cryptococcus meningitis and pulmonary cryptococcosis. 29 Seven studies, mostly retrospective (6/7) and single-centre (4/7), were included for the analysis of diagnostic performance. [30] [31] [32] [33] [34] [35] [36] The sensitivity of serum Ag was higher than that of blood cultures (87% vs 42%), and it was higher in AIDS patients (in whom disseminated disease with fungemia is most frequently observed) when compared with non-HIV immunocompromised subjects (95% vs 77%). However, data on non-HIV patients are mainly derived from solidorgan transplant recipients 33, 36 and the few data available in hemato-oncological patients do not allow separate performance analyses. 32, 35 In Cryptococcus meningitis, the sensitivity of both CSF Ag testing and culture was very high (97%). In pulmonary cryptococcosis as well as in infections at other sites, the sensitivity of the serum Ag was much lower (62% and 67%, respectively). 32, 35 An excellent specificity (ranging between 93-100%) both in serum and in CSF is reported from case-control studies. 37, 38 Falsepositive results have been more frequently reported with the latex agglutination tests than with EIA, with low titers (that is, 1:1-1:8) in most cases. 38 A single report of 12 falsepositive results of CSF antigenemia (of whom 75% were in patients with hematological malignancies, with CNS involvement in most of them) has been published. 39 High titers (X1:512) at baseline and/or in follow-up in both blood and CSF seem to be associated with severe or disseminated disease with fungemia and treatment failure, particularly in HIV-positive subjects. 32 Most patients with cryptococcal meningitis who responded to treatment had a fourfold decrease in CSF Ag titers (from a median of 1:256, range 0-1:10 6 at baseline to 1:64, range 0-1:8192 on day 7-40 of follow-up). 35 Therefore, serum and cerebrospinal fluid Cryptococcus antigen testing are both recommended to diagnose disseminated infection or meningitis, respectively (A II for both indications). As specific data on hemato-oncological patients are lacking, clinicians have to be aware of potential false-negative results of serum Cryptococcus Ag in this setting, especially in patients without fungemia/disseminated disease. There is less evidence for the follow-up of Cryptococcus Ag titers to assess the therapeutic response of infection and for prediction of outcome (C III and B III, respectively).
Mannan Ag (Mn)/anti-mannan Ab (A-Mn)
Non-culture-based methods for the detection of circulating Candida Ags, metabolites and antibodies have been developed for the diagnosis of IC: Mn, A-Mn Abs, enolase and arabinitol. Mn is a major component of the Candida cell wall, making up to 7% of the cell dry weight, and is one of the main Candida Ags that circulate in blood during infection. 40 ELISAs quantifying Mn Ag and A-Mn Abs are marketed as Platelia Candida Antigen and Platelia Candida Antibody (Bio-Rad Laboratories, Marnes-la-Coquette, France). 40, 41 These markers are not included in the revised EORTC/MSG criteria for diagnosis of IFD. 1 A systematic review of studies using ELISA (Platelia Candida Antigen and Antibody) to measure Mn and A-Mn in serum was performed. The target condition was IC, defined according to the revised EORTC/MSG diagnostic criteria. Sensitivity, specificity and diagnostic odds ratio (DOR) with 95% CIs were calculated for Mn, A-Mn and combined Mn/A-Mn testing.
Overall, 14 studies, including 453 IC cases and 767 controls, were reviewed. [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] The number of IC cases per study varied from 7 to 105, with a median of 25. A control group was included in 11 of 14 studies, and most frequently consisted of patients with similar risk factors but without IC, and sometimes with other documented infections. A total of four studies included healthy blood donors as controls. All studies but one were retrospective in design. 44 The cutoffs of 0.5 ng/mL for Mn and 10 arbitrary units/mL for A-Mn are defined as positive according to the manufacturer, whereas the values 0.25-0.5 ng/mL for Mn and 5-10 arbitrary units/mL for A-Mn are considered indeterminate. Most studies defined a positive result according to the cutoff value recommended by the manufacturer in a single serum sample.
In 14 studies (including hematological and ICU patients), Mn sensitivity was 58% (95% CI: 53-62), Mn specificity and DOR were 93% (95% CI: 91-94) and 18% (95% CI: 12-28), respectively. A-Mn sensitivity was 59% (95% CI: 54-65), specificity 83% (95% CI: 79-97) and DOR 12% (95% CI: 7-21). Combined Mn/A-Mn sensitivity was 83% (95% CI: 79-87), specificity 86% (95% CI: 82-90) and DOR 58% (95% CI: 27-122). Pooled overall values for sensitivity, specificity and DOR are outlined in Table 4 . Significant heterogeneity of the studies was detected. Persample sensitivity and specificity of combined Mn/A-Mn were assessed only in three and two studies, and was 62 and 96%, respectively. 56 In the specific subset of hematooncological patients, similar values were observed, with sensitivity in single studies ranging from 71 to 100%, specificity from 53 to 92% and diagnostic DOR from 23.3 to 115. In a single study in leukemic patients reporting separate data on tests' performance in proven/probable hepatosplenic candidiasis, sensitivity and specificity of combined Mn/A-Mn were 87 and 84%, respectively. 48 The sensitivity of both Mn and A-Mn varied for different Candida species, and was the highest for C. albicans, followed by C. glabrata and C. tropicalis. 45, 49 The temporal relationship between Mn/A-Mn detection in serum compared with conventional methods was also analyzed. An advantage in early diagnosis using Mn/A-Mn detection was reported in five studies, both in hematological and ICU patients. 46, 48, 52, 53, 55 Mn-and A-Mn-positive results preceded blood cultures in 73% of 45 patients with candidemia by a mean of 6 and 7 days, respectively. 55 In 21 patients with hepatosplenic IC, 18 (86%) were Mn-and/or A-Mnpositive at a median of 16 days before radiological detection of liver or spleen lesions. 48 Based on the literature review, Mn and A-Mn offer a diagnostic aid in patients with suspected IC. The panel recommended combined Mn/A-Mn tests as being more useful than either type of test alone (B II). The combined Mn/A-Mn testing was found to be more helpful for diagnosing hepatosplenic candidiasis (B III), a specific pathology in hemato-oncological patients without microbiological documentation in the majority of cases, than for candidemia (C II), in which non-culture-based methods may be of lesser utility.
More data specifically addressing the tests' performance and cost-effectiveness in hemato-oncological patients are needed to better define their role in the early management of IFD. New versions of the ELISA Mn and A-Mn tests (Platelia Candida Antigen plus and Antibody plus) are now available with revised recommended cutoffs: their performance should, however, be assessed in new clinical studies.
PCR for the diagnosis of IA
In IFD, PCRs have been mainly investigated in IA, whereas fewer data are available for other fungal pathogens, in particular for Candida spp. The present assessment will thus focus on PCRs for Aspergillus spp. in hematological patients. In contrast to GM detection, which relies on a single commercially available laboratory test with its own calibrators and the use of a simple ELISA reader, the multiple PCR assays reported in the literature present important technical differences regarding the gene targets (FKS gene, mitochondrial DNA, 18S rRNA, 5.8S rRNA, 28S rRNA), the detection systems (TaqMan, FRET), the primers (A. fumigatus-specific, Aspergillus spp. or panfungal), the clinical specimen (whole blood, serum, BAL fluid, tissue biopsies), the volume (0.2-10 mL), the DNA extraction (manual, automated) and the PCR itself (endpoint PCR, nested PCR, real-time quantitative PCR). 57 A single PCR assay format used worldwide is an unrealistic goal, given the different platforms available. Instead, a MIQE (for Minimal Information for publication of Quantitative real-time PCR Experiments) consensus is now being defined for the design and the report of real-time quantitative PCR (qPCR) assays, 58 which can be followed by any laboratory to get reproducible and reliable results. One of the most important issues is the limitation of false-positive and false-negative results. The current trend is to use qPCR because this format decreases the risk of contamination with previously amplified products, and can control the yield of amplification to give reliable quantitative results. 59 A recent meta-analysis of studies in hematological patients with IA using different home-made PCRs in blood reported a sensitivity of 75% (95% CI: 54-88) and a specificity of 87% (95% CI: 78-93) for two PCR-positive results, and a sensitivity of 88% (95% CI: 75-95) and a specificity of 75% (95% CI: 63-84) for a single positive result. 60 When used as a screening test, authors favor the negative predictive value of the results. 61, 62 For the diagnosis of IA using PCR in BAL fluids, another meta-analysis calculated a mean sensitivity of 79% (95% CI: 72.8-83.1) and a mean specificity of 94% (95% CI: 92.1-95.0). 63 Some clinical studies also suggest a possible role of PCR monitoring in guiding antifungal therapy.
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Table 4
Overall pooled values, with 95% CI, of sensitivity, specificity and DOR of Mn, A-Mn and combined Mn/A-Mn testing Despite these encouraging results, PCRs are not considered in the revised EORTC/MSG consensus definitions for IFD. 1 The main reason is the lack of standardization, and thus of inter-laboratory reproducibility of the analyses.
The main source of procedural false positivity is environmental contamination with previously amplified products. To limit this risk, standard procedures should be followed (unidirectional workflow, physically separated laboratories for pre-, per-and post-PCR analysis, the use of aerosolresistant pipettes and tips, and laminar flow hoods). Enzymatic prevention of contamination using uracil-Nglycosylase can also reduce the risk of false-positives. Nevertheless, the main methodological innovation was the development of qPCR, as its closed analytical system substantially reduces the risk of contamination by amplified DNA from environmental aerosols. Another possible major source of procedural false-positive results is the presence of fungal spores or DNA in the reagents. Therefore, the DNA extraction process should limit the volume and number of reagents, and enzymes used. Regular tests of both commercial and 'in-house' reagents by negative extraction controls should be performed, although very low-level contamination cannot be completely excluded.
Systematic control of the amplification yield for each clinical sample with an internal control of the reaction is required, as a slight decrease in the amplification yield, due to residual PCR inhibitors after DNA extraction, can lead to a false-negative result. By adding the same quantity of internal control in the PCR mix, the same result (expressed as a quantitative number of PCR cycles) is expected for every sample. If not, this suggests the possibility of a partial amplification inhibition and the interpretation of the result must integrate this limitation.
The current status of the technical and clinical validation of PCR for Aspergillus in blood and other biological fluids does not allow a recommendation for clinical use, mainly due to a lack of standardization and inter-laboratory reproducibility.
The European Aspergillus PCR Initiative (EAPCRI) was launched in 2006 with the aim of providing optimized, standardized laboratory protocols for implementation of Aspergillus PCR in the clinical routine. Different quality control panels were distributed to 24 centers. One quality control sample consisted of blood spiked with serial dilutions of Aspergillus fumigatus DNA. There was no statistical difference between the mean PCR efficiency using different platforms or PCR targets. Another quality control sample consisted of blood spiked with A. fumigatus conidia. Meta-regression analysis showed positive correlations between sensitivity and extraction protocols incorporating the use of bead-beating, white cell lysis buffer, a starting volume of 3 mL, and an elution volume less than 100 mL.
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A recent reanalysis reinforces the importance of the different stages of DNA extraction. 65 New, standardized, commercially available PCRs might also contribute to improve inter-laboratory reproducibility of results; however, these expensive and technically complex assays need a validation in specific clinical settings at high risk of IFD.
Conclusion
This evidence-based review of currently available nonculture-based diagnostic markers of IFD in hematooncological patients strongly supports the use of GM for IA (A II) and of Cryptococcus Ag for cryptococcosis (A II), whereas evidence for the use of BG and Mn/A-Mn tests is moderate (B II and B III/C II, respectively). For these two last markers, the optimal cutoffs for positivity, as well as the number of samples required for confirmation of positivity, should be better defined. For PCR assays, lack of inter-laboratory standardization of analytical procedures does not allow recommendations for their clinical use. The above recommendations are based on results obtained by comparing these biomarkers with the EORTC/MSG criteria of IFD integrating clinical, radiological and microbiological signs. Thus, IFD remains often unproven, and the lack of a more reliable diagnostic standard precludes an unequivocal interpretation of positive and negative results for all these biomarkers. The current recommendations apply for adults, whereas additional analyses are warranted for pediatric patients. Moreover, the grading system used to weigh and compare the quality of evidence has been designed for therapeutic recommendations. Using this grading, an A I level of recommendation could not be reached for any of these fungal markers, which emphasizes the need for randomized controlled studies to define their clinical utility in guiding patients' management. Their role and cost-effectiveness in providing a more rapid and accurate diagnosis of IFD, allowing early initiation of appropriate antifungal therapy and ideally reducing the empirical use of antifungal drugs in patients without IFD, should be further assessed. Alternatively, a grading system specifically designed for diagnostic tests should be developed.
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